Momelotinib: First Approval

Drugs. 2023 Dec;83(18):1709-1715. doi: 10.1007/s40265-023-01964-8.

Abstract

Momelotinib (OJJAARA) is an oral Janus kinase 1 and 2 (JAK1/JAK2) and activin A receptor, type I (ACVR1) inhibitor that has been developed for the treatment of myelofibrosis (MF). In September 2023, momelotinib was approved in the USA for the treatment of intermediate or high-risk MF, including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. This article summarizes the milestones in the development of momelotinib leading to this first approval for MF.

Publication types

  • Review

MeSH terms

  • Adult
  • Benzamides / pharmacology
  • Humans
  • Janus Kinase 2
  • Polycythemia Vera* / complications
  • Primary Myelofibrosis* / complications
  • Primary Myelofibrosis* / drug therapy
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use

Substances

  • N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
  • Janus Kinase 2
  • Pyrimidines
  • Benzamides